CL2013002740A1 - Compuestos macrociclicos analogos de sangliferina, inhibidores de la ciclofilina; procedimiento de preparacion; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como infeccion por vhc o vih, o uso como inmunosupresor o agente antiinflamatorio. - Google Patents

Compuestos macrociclicos analogos de sangliferina, inhibidores de la ciclofilina; procedimiento de preparacion; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como infeccion por vhc o vih, o uso como inmunosupresor o agente antiinflamatorio.

Info

Publication number
CL2013002740A1
CL2013002740A1 CL2013002740A CL2013002740A CL2013002740A1 CL 2013002740 A1 CL2013002740 A1 CL 2013002740A1 CL 2013002740 A CL2013002740 A CL 2013002740A CL 2013002740 A CL2013002740 A CL 2013002740A CL 2013002740 A1 CL2013002740 A1 CL 2013002740A1
Authority
CL
Chile
Prior art keywords
hcv
pharmaceutical composition
hiv infection
viral infections
inflammatory agent
Prior art date
Application number
CL2013002740A
Other languages
English (en)
Inventor
Steven Moss
Matthew Alan Gregory
Barrie Wilkinson
Original Assignee
Neurovive Pharmaceutical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1105293.3A external-priority patent/GB201105293D0/en
Priority claimed from GBGB1113629.8A external-priority patent/GB201113629D0/en
Priority claimed from GBGB1202060.8A external-priority patent/GB201202060D0/en
Application filed by Neurovive Pharmaceutical Ab filed Critical Neurovive Pharmaceutical Ab
Publication of CL2013002740A1 publication Critical patent/CL2013002740A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/061,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

COMPUESTO DE FÓRMULA (1) DONDE X 1 REPRESENTA -0R 1 ,-NR1 R2 O R3 Y R 1 R2 Y R3 SE DEFINEN TAL COMO EN EL PLIEGO DE REIVINDICACIONES. USO DE UN COMPUESTO DE FÓRMULA (1) EN LA PREPARACIÓN DE UN PRODUCTO FARMACÉUTICO ÚTIL PARA TRATAR INFECCIONES VIRALES TALES COMO INFECCIÓN VHC O VIH O COMO UN INMUNOSUPRESOR O UN AGENTE ANTI-INFLAMATORIO. COMPOSICIÓN FARMACÉUTICA; Y PROCEDIMIENTO PARA PREPARAR DICHO COMPUESTO. COMPUESTO DE FÓRMULA (VI) DONDE X2 , X3 , X4 , X5 , X6 , R4 , R 5, R6 , R7 , R8 , R9, Y N SE DEFINEN TAL COMO EN EL PLIEGO DE REIVINDICACIONES.        
CL2013002740A 2011-03-29 2013-09-25 Compuestos macrociclicos analogos de sangliferina, inhibidores de la ciclofilina; procedimiento de preparacion; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como infeccion por vhc o vih, o uso como inmunosupresor o agente antiinflamatorio. CL2013002740A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1105293.3A GB201105293D0 (en) 2011-03-29 2011-03-29 Novel compounds and methods for their production
GBGB1113629.8A GB201113629D0 (en) 2011-08-08 2011-08-08 Novel compounds and methods for their production
GBGB1202060.8A GB201202060D0 (en) 2012-02-07 2012-02-07 Novel compounds and methods for their production

Publications (1)

Publication Number Publication Date
CL2013002740A1 true CL2013002740A1 (es) 2014-07-11

Family

ID=46001313

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013002740A CL2013002740A1 (es) 2011-03-29 2013-09-25 Compuestos macrociclicos analogos de sangliferina, inhibidores de la ciclofilina; procedimiento de preparacion; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como infeccion por vhc o vih, o uso como inmunosupresor o agente antiinflamatorio.
CL2013002739A CL2013002739A1 (es) 2011-03-29 2013-09-25 Compuesto macrociclicos analogo de sangliferina, inhibidor de la ciclofilina; forma cristalina solida y forma de polimorfo cristalino; procedimientos para prepararlos; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como vhc o vih o uso como inmunosupresor o agente antiinflamatorio.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2013002739A CL2013002739A1 (es) 2011-03-29 2013-09-25 Compuesto macrociclicos analogo de sangliferina, inhibidor de la ciclofilina; forma cristalina solida y forma de polimorfo cristalino; procedimientos para prepararlos; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como vhc o vih o uso como inmunosupresor o agente antiinflamatorio.

Country Status (29)

Country Link
US (2) US9090657B2 (es)
EP (2) EP2691413B1 (es)
JP (2) JP6118792B2 (es)
KR (2) KR101911484B1 (es)
CN (3) CN103635484B (es)
AR (1) AR085724A1 (es)
AU (2) AU2012235961B2 (es)
BR (2) BR112013024965A2 (es)
CA (2) CA2830831C (es)
CL (2) CL2013002740A1 (es)
CY (2) CY1116318T1 (es)
DK (2) DK2691413T3 (es)
EA (2) EA023848B1 (es)
ES (2) ES2533438T3 (es)
HK (2) HK1189237A1 (es)
HR (2) HRP20150184T1 (es)
IL (2) IL228509B (es)
JO (1) JO3063B1 (es)
MX (2) MX345352B (es)
MY (2) MY170637A (es)
PL (2) PL2691413T3 (es)
PT (2) PT2691412E (es)
RS (2) RS53964B1 (es)
SG (2) SG193568A1 (es)
SI (2) SI2691412T1 (es)
TW (1) TWI525098B (es)
UY (1) UY33993A (es)
WO (2) WO2012131377A1 (es)
ZA (2) ZA201307149B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2541853T3 (es) 2010-02-09 2015-07-27 Neurovive Pharmaceutical Ab Compuestos basados en sangliferina
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
CN103130734A (zh) * 2011-12-01 2013-06-05 上海药明康德新药开发有限公司 一种合成1,2-吗啉盐酸盐的方法
CN105695541B (zh) * 2016-03-10 2019-03-15 苏州华赛生物工程技术有限公司 一种抗生素nvp018中间体的分离纯化方法
KR20180036522A (ko) 2016-09-30 2018-04-09 (주)나노믹스 스틸벤 유도체 및 그 제조 방법
US10857150B2 (en) 2016-11-18 2020-12-08 Abliva Ab Use of sanglifehrin macrocyclic analogues as anticancer compounds
CN112410353B (zh) * 2019-08-23 2023-01-24 上海医药工业研究院 一种fkbS基因、含其的基因工程菌及其制备方法和用途
CN115028681B (zh) * 2022-08-11 2022-11-15 中国科学院微生物研究所 一种降解亲环素a的嵌合体化合物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
BRPI0613142A2 (pt) * 2005-06-17 2010-12-21 Novartis Ag uso de sangliferina em hcv
AU2008204344B2 (en) 2007-01-04 2013-01-31 Debiopharm Sa Non-immunosuppressive cyclosporin for treatment of Ullrich congenital muscular dystrophy
CN102224242B (zh) 2008-09-24 2014-09-24 中国科学院上海有机化学研究所 新基因簇
CN101691575B (zh) * 2008-09-24 2013-06-05 中国科学院上海有机化学研究所 一种萨菲菌素的生物合成基因簇
ES2541853T3 (es) * 2010-02-09 2015-07-27 Neurovive Pharmaceutical Ab Compuestos basados en sangliferina
WO2011098805A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098808A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
CA2822347C (en) * 2010-12-20 2019-11-05 Neurovive Pharmaceutical Ab Sanglifehrin derivatives and methods for their production
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه

Also Published As

Publication number Publication date
DK2691412T3 (en) 2015-04-07
HK1189237A1 (en) 2014-05-30
IL228509A0 (en) 2013-12-31
CY1116318T1 (el) 2017-02-08
EP2691412A1 (en) 2014-02-05
AR085724A1 (es) 2013-10-23
US20120251581A1 (en) 2012-10-04
EP2691412B1 (en) 2014-12-24
UY33993A (es) 2012-10-31
AU2012235961B2 (en) 2016-09-01
US20140038885A1 (en) 2014-02-06
CN103635484B (zh) 2017-05-10
IL228508B (en) 2018-01-31
KR20140057481A (ko) 2014-05-13
EP2691413B1 (en) 2014-12-24
CN103635484A (zh) 2014-03-12
JP2014514290A (ja) 2014-06-19
MX345352B (es) 2017-01-26
US9139613B2 (en) 2015-09-22
SI2691412T1 (sl) 2015-05-29
AU2012235880B2 (en) 2016-11-17
RS53964B1 (en) 2015-08-31
CL2013002739A1 (es) 2014-07-11
EP2691413A1 (en) 2014-02-05
ZA201307149B (en) 2015-04-29
WO2012131371A1 (en) 2012-10-04
JP6118793B2 (ja) 2017-04-26
MX345351B (es) 2017-01-26
SG193569A1 (en) 2013-11-29
MY170618A (en) 2019-08-21
WO2012131377A1 (en) 2012-10-04
TW201300398A (zh) 2013-01-01
IL228508A0 (en) 2013-12-31
CA2830827A1 (en) 2012-10-04
ZA201307231B (en) 2015-05-27
MX2013011051A (es) 2014-03-13
KR20140071958A (ko) 2014-06-12
EA201391396A1 (ru) 2014-02-28
DK2691413T3 (en) 2015-04-07
AU2012235880A1 (en) 2013-10-17
CA2830831C (en) 2020-03-10
KR101911484B1 (ko) 2018-10-24
JP6118792B2 (ja) 2017-04-26
MY170637A (en) 2019-08-21
BR112013024965A2 (pt) 2017-04-18
MX2013011043A (es) 2014-04-25
HK1189236A1 (en) 2014-05-30
CA2830831A1 (en) 2012-10-04
BR112013024974A2 (pt) 2016-09-06
PL2691412T3 (pl) 2015-08-31
SG193568A1 (en) 2013-11-29
PT2691413E (pt) 2015-03-25
PT2691412E (pt) 2015-03-25
CY1116186T1 (el) 2017-02-08
AU2012235961A1 (en) 2013-10-10
TWI525098B (zh) 2016-03-11
US9090657B2 (en) 2015-07-28
ES2533438T3 (es) 2015-04-10
KR101868084B1 (ko) 2018-06-18
EA023907B1 (ru) 2016-07-29
JP2014510746A (ja) 2014-05-01
ES2533437T3 (es) 2015-04-10
CN103619869A (zh) 2014-03-05
EA023848B1 (ru) 2016-07-29
CN107417766A (zh) 2017-12-01
EA201391399A1 (ru) 2014-02-28
RS53963B1 (en) 2015-08-31
CA2830827C (en) 2020-03-10
PL2691413T3 (pl) 2015-05-29
IL228509B (en) 2018-02-28
JO3063B1 (ar) 2017-03-15
HRP20150187T1 (en) 2015-06-05
HRP20150184T1 (hr) 2015-05-08
SI2691413T1 (sl) 2015-05-29
CN103619869B (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
CL2013002740A1 (es) Compuestos macrociclicos analogos de sangliferina, inhibidores de la ciclofilina; procedimiento de preparacion; intermediario; composicion farmaceutica; y uso en el tratamiento de infecciones virales tales como infeccion por vhc o vih, o uso como inmunosupresor o agente antiinflamatorio.
CY1122246T1 (el) Πολυκυκλικες ενωσεις καρβαμοϋλπυριδονης και φαρμακευτικη χρηση αυτων
DOP2022000240A (es) Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
SV2005001920A (es) " compuestos nucleosidos para el tratamiento de infecciones virales "
CO6680667A2 (es) Derivados ester de ácido borónico cíclico y sus usos terapéuticos
GEP20186838B (en) 5-phenoxy-3h-pyrimidin-4-one derivatives and their usage as hiv reverse transcriptase inhibitors
TR201905009T4 (tr) Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
NZ598766A (en) Macrocyclic integrase inhibitors
MX2010005292A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
MX2009005603A (es) Compuestos de urea policiclicos antibacterianos.
EA201390233A1 (ru) Фармацевтические композиции
AR063942A1 (es) Compuestos de oximilo aciclico inhibidores de proteasa del virus de hepatitis c
UY30544A1 (es) Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones
EA201170537A1 (ru) Ингибиторы вич-интегразы
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.
NI200700176A (es) Compuestos peptídicos
MX358189B (es) Derivados de pirimidina para el tratamiento de enfermedades bacterianas.